Trial reportThe Journal of infectious diseases2015
Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.
Trial report in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01654224 (Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting), which is not on this map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Trivalent and quadrivalent seasonal influenza vaccine in adults aged 60 and older: a systematic review and network meta-analysis.BMJ evidence-based medicine · 2024Pooled it
- Systematic review of influenza vaccine effectiveness against laboratory-confirmed influenza among older adults living in aged care facilities.Human vaccines & immunotherapeutics · 2023Pooled it
- Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2019Pooled it
- Boosting effect of high-dose influenza vaccination on innate immunity among elderly.JCI insight · 2025Trial
- Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: Lessons learned.Human vaccines & immunotherapeutics · 2018Trial
- High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.Vaccine · 2016Trial
- State-of-the-art of the high dose influenza vaccine in Spain.Frontiers in immunology · 2026Review
- A scoping review of randomised controlled trials of vaccines that recruited care home residents: lessons for future trials.Age and ageing · 2025Article
- [Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax TetraJournal of preventive medicine and hygiene · 2022Article
- [High-dose trivalent influenza vaccine. Efficacy and effectiveness].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Review
- Frailty Is Associated With Increased Hemagglutination-Inhibition Titers in a 4-Year Randomized Trial Comparing Standard- and High-Dose Influenza Vaccination.Open forum infectious diseases · 2020Article
- Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.Vaccine · 2017Article
- Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals.Human vaccines & immunotherapeutics · 2015Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite vaccination, residents of long-term-care facilities (LTCFs) remain at high risk of influenza-related morbidity and mortality. More-effective vaccine options for this population are needed.
methodsWe conducted a single-blinded, randomized, controlled trial comparing high-dose (HD) to standard-dose (SD) inactivated influenza vaccine (IIV) in 205 frail, elderly residents of LTCFs during the 2011-2012 and 2012-2013 influenza seasons. Hemagglutination inhibition (HI) antibody titers were measured at baseline and 30 and 180 days following vaccination.
resultsA total of 187 subjects (91%) completed the study. The mean age was 86.7 years. Geometric mean titers (GMTs) were significantly higher (P < .05) at day 30 for HD recipients, compared with SD recipients, for all comparisons except influenza A(H1N1) during 2012-2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1N1] during 2012-2013). GMTs for HD and SD recipients during 2011-2012 were as follows: influenza A(H1N1), 78 (95% confidence interval [CI], 45-136) and 27 (95% CI, 17-44), respectively; influenza A(H3N2), 26 (95% CI, 17-40) and 10 (95% CI, 7-15), respectively; and influenza B, 26 (95% CI, 19-35) and 14 (95% CI, 11-18), respectively. During 2012-2013, GMTs for HD and SD recipients were as follows: influenza A(H1N1), 46 (95% CI, 33-63) and 50 (95% CI, 37-67); influenza A(H3N2), 23 (95% CI, 18-31) and 14 (95% CI, 11-18), respectively; and influenza B, 26 (95% CI, 21-32) and 17 (95% CI, 14-22), respectively. GMTs were significantly higher at day 180 for HD recipients, compared with SD recipients, for influenza A(H3N2) in both years (P < .001).
conclusionsAmong frail, elderly residents of LTCFs, HD influenza vaccine produced superior responses for all strains except influenza A(H1N1) in 2012-2013. CLINICAL TRIALS REGISTRATION: NCT01654224.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.